APA (7th ed.) Citation

AV, G., B, S., C, K., R, F., MA, P., M, E., . . . RA, M. (2023). Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Blood advances, 7(14), 3725. https://doi.org/10.1182/bloodadvances.2022009478

Chicago Style (17th ed.) Citation

AV, Geerlinks, et al. "Alemtuzumab and CXCL9 Levels Predict Likelihood of Sustained Engraftment After Reduced-intensity Conditioning HCT." Blood Advances 7, no. 14 (2023): 3725. https://doi.org/10.1182/bloodadvances.2022009478.

MLA (9th ed.) Citation

AV, Geerlinks, et al. "Alemtuzumab and CXCL9 Levels Predict Likelihood of Sustained Engraftment After Reduced-intensity Conditioning HCT." Blood Advances, vol. 7, no. 14, 2023, p. 3725, https://doi.org/10.1182/bloodadvances.2022009478.